AI assistant
Mankind Pharma Limited Earnings Release 2026
61869_rns_2026-05-19_914a8795-7e1c-4284-a533-6bfa9a540e47.pdf
Earnings Release
Open in viewerOpens in your device viewer
MANKIND PHARMA LIMITED
Serving Life
May 19, 2026
BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: 543904
Symbol: MANKIND
Dear Sir/ Madam,
Subject: Press Release – Q4FY26 & FY26
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Financial Results of the Company for the quarter and financial year ended on March 31, 2026.
The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com.
You are requested to kindly take the above information on your records.
Thanking You,
Yours Faithfully,
For Mankind Pharma Limited
HITESH
KUMAR JAIN
Digitally signed by
HITESH KUMAR JAIN
Date: 2026.05.19
20:03:24 +05'30'
Hitesh Kumar Jain
Company Secretary &
Compliance Officer
Encl.: A/a
MANKIND PHARMA LIMITED
Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : [email protected] • www.mankindpharma.com
Press Release
M
Mankind
Serving Life
Mankind Pharma revenue up by 11.8%; Adj. EBITDA margin at 27.1% in Q4FY26
New Delhi, India, 19 May, 2026: Mankind Pharma (BSE: 543904 | NSE: MANKIND) India’s fourth largest pharmaceutical Company today announced its financial results for the fourth quarter and full year ended 31st March 2026. The information mentioned in this release is based on consolidated financial statements.
Mr. Rajeev Juneja – Vice Chairman & Managing Director
- Revenue increased ~12% YoY with adj. EBITDA margins¹ of 27.1%
- Overall domestic business (ex CH) grew by ~13% led by:
- double digit growth in Mankind domestic business led by 14.7% in cardiac and 11.6% in anti-diabetes (120 bps YoY increase in chronic share to ~40%)
- sequential growth recovery in key acute therapies like Gastro, VMN, etc.
- strong double digit growth in BSVs domestic business
- OTC business grew by 20% led by strong growth in e-commerce; International business witnessed muted growth due to geo-political headwinds
-
We are on track in strengthening scale and advancing specialization through four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and super specialty BSV portfolio to deliver long-term sustainable growth.
-
Adjusted with one time impact of labour code regulations and other non-recurring cost (Refer note 10 of Consolidated Financial Results)
Press Release
M
Mankind
Serving Life
Q4 FY26 Performance Summary
- Revenue from Operations at INR 3,443 Cr, up by 11.8% YoY
- Domestic revenue at INR 2,886 Cr, up 13.4%, Exports at INR 557 Cr, up 4.2% YoY
- Adjusted EBITDA margin of 27.1%, up by 400 bps YoY and PAT margin of 16.2%, up 230 bps YoY
-
Diluted EPS¹ of INR 13.4, up 30.3% YoY (FV Re.1)
-
Diluted EPS not annualised
FY26 Performance Summary
- Revenue from Operations at INR 14,278 Cr, up by 17.0% YoY
- Domestic revenue at INR 12,217 Cr, up 14.4%, Exports at INR 2,061 Cr, up 34.5% YoY
- Adjusted EBITDA margin of 25.4% and PAT margin of 13.6%
- Diluted EPS¹ of INR 46.3 down by 5.7% YoY (FV Re.1)
-
CFO to EBITDA ratio was 89% for FY26 vs 80% in FY25
-
Diluted EPS not annualised
Domestic Business¹
- Domestic revenue² increased 13% YoY driven by double digit growth in Mankind business, supported by strong growth in BSV specialty business
- Secondary sales growth of 8.7% vs 10.7% IPM³ in Q4FY26 – primarily due to
- strong performance in chronic growth supported by 14.7% in Cardiac and 11.6% in Anti-Diabetes
- muted growth in anti-infectives partially offset by sequential recovery in Gastro, VMN, Derma etc.
- Strong growth in key focused brands:
- outperformance in key acute brands like Cefakind-CV (1.3x), Nurokind-LC (1.1x), Pantakind (1.4x), Dydroboon (1.9x) etc in Q4FY26
- c.16.5% growth in Telmikind family; 23.7% in Lipirose; 28.7% in Statpure in cardiac during Q4FY26
- Glizid brand family crossed Rs 230 Cr in MAT Mar'26 (35%+ growth)
- Healthy growth in BSVs key brands - Foligraf (52%), HMG (40%), Ossopan (72%), Lactare (46%) and Anti-D having 100% market share has grown 10%
-
Consistently maintained #1 rank over last 9 years with prescription share of 15.1%
-
As per IQVIA March-2026 // 2. Denotes reported number // 3. Ex-GLP1 - innovator
Consumer Healthcare Business¹
- Revenue² growth of 20% YoY in Q4FY26 primarily driven by strong growth in Manforce, Prega News, Gasofast and Nimulid
- MT & E-Com share increased to 13% in FY26 as compared to 9% in FY25 supported by 57% growth
-
Healthy growth in secondary sales² for Gas-o-fast, Prega News and Ova news of 24%, 28% and 65% YoY respectively in Q4FY26
-
As per IQVIA / IQVIA Retail, March-2026 // 2. Denotes reported number
Press Release
M
Mankind
Serving Life
Exports
- Revenue from International business witnessed muted growth of 4% YoY in Q4FY26 impacted due to geo-political headwinds
- Mankind (excluding BSV) has launched 4 new products in FY26 taking the total launched products to 48 in US
Consolidated Profit & Loss Account
| In INR Crore | Q4 FY26 | Q4 FY25 | YoY% | Q3 FY26 | QoQ% |
|---|---|---|---|---|---|
| Revenue from Operations | 3,443 | 3,079 | 11.8% | 3,567 | -3.5% |
| Gross Margins % | 72.2% | 71.6% | 60 bps | 72.6% | (40 bps) |
| EBITDA | 910 | 686 | 32.7% | 816 | 11.5% |
| EBITDA Margin % | 26.4% | 22.3% | 410 bps | 22.9% | 350 bps |
| Adjusted EBITDA | 933¹ | 711² | 31.1% | 923¹ | 0.8% |
| Adjusted EBITDA Margin % | 27.1%¹ | 23.1%² | 400 bps | 25.9%¹ | 120 bps |
| PAT | 559 | 429 | 30.4% | 414 | 35.2% |
| PAT Margin % | 16.2% | 13.9% | 230 bps | 11.6% | 460 bps |
- Adjusted with one time impact of labour code regulations and other non-recurring cost (Refer note 10 of Consolidated Financial Results)
- Adjusted with one time M&A related expenses & other non-recurring cost
| In INR Crore | FY26 | FY25 | YoY% |
|---|---|---|---|
| Revenue from Operations | 14,278 | 12,207 | 17.0% |
| Gross Margins % | 71.6% | 71.4% | 20 bps |
| EBITDA | 3,499 | 3,030 | 15.5% |
| EBITDA Margin % | 24.5% | 24.8% | (30 bps) |
| Adjusted EBITDA | 3,629¹ | 3,159² | 14.9% |
| Adjusted EBITDA Margin% | 25.4%¹ | 25.9%² | (50 bps) |
| PAT | 1,938 | 2,007 | -3.4% |
| PAT Margin % | 13.6% | 16.4% | (280 bps) |
| Diluted EPS (INR) | 46.3 | 49.1 | -5.7% |
| Cash EPS (INR) | 68.1 | 64.4 | 5.6% |
- Adjusted with one time impact of labour code regulations and other non-recurring cost (Refer note 10 of Consolidated Financial Results)
- Adjusted with one time M&A related expenses & other non-recurring cost
Segmental Revenue Break Up
Press Release
M MANKIND Pharma
| In INR Crore | Q4 FY26 | Q4 FY25 | YoY% | Q3 FY26 | QoQ% |
|---|---|---|---|---|---|
| Domestic | 2,886 | 2,544 | 13.4% | 3,046 | -5.3% |
| • Domestic (Ex-CH) | 2,673 | 2,366 | 12.9% | 2,843 | -6.0% |
| • Consumer Healthcare (CH) | 213 | 178 | 19.8% | 203 | 5.0% |
| Exports | 557 | 535 | 4.2% | 521 | 7.0% |
| Total | 3,443 | 3,079 | 11.8% | 3,567 | -3.5% |
| In INR Crore | FY26 | FY25 | YoY% | ||
| --- | --- | --- | --- | ||
| Domestic | 12,217 | 10,675 | 14.4% | ||
| • Domestic (Ex-CH) | 11,338 | 9,866 | 14.9% | ||
| • Consumer Healthcare (CH) | 879 | 809 | 8.7% | ||
| Exports | 2,061 | 1,532 | 34.5% | ||
| Total | 14,278 | 12,207 | 17.0% |
Earning concall Details
| Date | 20th MAY, 2026 |
|---|---|
| Time | 12:00 pm – 01:00 pm IST |
| Zoom Link | Click here |
About Mankind Pharma
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women's health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 750 scientists.
For more information, visit www.mankindpharma.com
Press Release
M Mankind!Serving Life
Safe Harbour Statement
The statements, are as on date and may contain forward-looking statements like the words "believe", "expects", "anticipate", "aim", "will likely result", "Would", "will continue", "contemplate" "intends", "plans", "estimates", "seek to", "future", "objective", "projects", "goal", "likely", "Project", "should", "potential" "will", "may", "targeting" or other words of similar expressions/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward-looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance.
The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith. Also, Company assume no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events, or otherwise.
For Queries Contact
Mankind Pharma - Investor Relations & Strategy
Abhishek Agarwal
Email address: [email protected]
Contact Number: +91-11-46846700
Mankind Pharma - Corporate Communication
Natasha Raj
Email address: [email protected]
Contact Number: 011-46846700 Ext: 3201
Adfactors PR - Investor Relations / Public Relations
Smit Shah / Apoorva Sharma
Email address: [email protected] / [email protected]
Contact Number: +91 9870789596 / +91 9999739452